Founded by Flagship Pioneering, Empress re-imagines the process of small molecule drug discovery. Our bioplatform harnesses the power of evolution, human molecular and genetic data, and artificial intelligence to focus on endogenous sources of inherently drug-like small molecules as a uniquely qualified source of potential drugs.

Our mission is to generate transformative drug candidates that get to the clinic faster and cheaper, with a higher probability of success.


Biotechnology

Health Care

Empress Therapeutics

Jason Park

Murray McKinnon, Ph.D.

Sabrina Yang

Kevin Kreutter

The Research and Scientists team at Empress Therapeutics leverages cutting-edge techniques in synthetic biology, chemical biology, and chemoproteomics to identify and develop novel small molecule drug candidates. By utilizing a combination of human molecular data, genetic data, and artificial intelligence, they accelerate the discovery process to produce transformative medicines with higher success probabilities, aiming to bring them to clinical trials more efficiently and cost-effectively.

Research and Scientists

About

Team members

Other teams at Empress Therapeutics

Leadership Team